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Cancer may be one of the oldest diseases on earth. Since advances 
in medicine have significantly increased our lifespan, cancer has now 
become one of our biggest “natural” enemies. At the start of the “war 
on cancer” 40 years ago, we had some basic misconceptions about 
cancer. When Payton Rous, father of the Rous sarcoma oncovirus, won 
the Nobel Prize in 1966, he criticized the concept that cancer could 
be caused by somatic mutations, espousing the idea that all cancers 
were caused by viruses [1,2]. As late as 1978 Isaiah Fidler, a Houston 
oncologist, reported that cancer included “one cause, one mechanism 
and one cure” [3]. It was just a matter of finding the right cytotoxins in 
the right combination [4]. We had not yet realized that cancer could be 
identified at base-pair resolutions [5]. In The Art of War [6], Sun Tzu, 
who considered war a necessary evil, prophesized “Know your enemy”. 
Given our present and growing knowledge of our enemy cancer, we 
should not have to consider cancer a necessary evil. Since the beginning 
of this millennium, we have gained a much better understanding of 
this enemy. Nevertheless, we are still challenged by cancer’s limitless 
replicative potential [7,8] and its seemingly illimitable power to survive, 
evade, invade and metastasize.
A major problem for cancer therapy is that it exhibits hundreds 
of different genotypes defined by substantial numbers of mutations in 
a wide variety of genes/proteins. To simplify this diversity, Hanahan 
and Weinberg [7,8] defined eight major cancer hallmarks that control 
cell homeostasis and proliferation. These include self-sufficiency 
in growth signals, insensitivity to growth-inhibitory (anti-growth) 
signals, evasion of apoptosis, limitless replicative potential, sustained 
angiogenesis, tissue invasion and metastasis, reprogramming energy 
metabolism and evasion of immune surveillance. They also considered 
that unstable genomes and inflammation could advance multiple 
cancer hallmarks. 
More recently Vogelstein et al. [5] defined a cancer genome 
landscape, describing cancers as “pathway diseases” with two to 
eight mutations in genes that provide selective growth advantages 
to tumors referred to as “driver” mutations. These come from a class 
of 12 signaling pathways that regulate three core cellular processes: 
cell fate, cell survival and genome maintenance. With knowledge of 
cancer’s molecular mechanisms, treatment strategies using mutation-
specific, small molecule drugs or monoclonal antibodies have been 
developed to specifically target some cancers as defined in cancer 
hallmarks and “driver gene” pathways. One example is the treatment 
of B-RAF oncoprotein, a major participant in a driver pathway in 
melanoma, which provides self-sufficiency of growth signals [9,10]. 
However, tumors treated with B-RAF inhibitors, like other approaches 
using these strategies, often develop resistance after treatment and 
tumors reappear. This is a common cancer therapeutic inadequacy. 
Furthermore, BRAF mutations in colorectal cancers are not responsive 
to these inhibitors [11]. Thus, new treatment modalities are needed 
to treat cancer, especially ones that can effectively ablate tumors 
and enhance immune mechanisms. My laboratory is investigating 
a relatively new therapy that modifies two cancer hallmarks without 
drugs: evasion of apoptosis and sustained angiogenesis [12]; however, 
the latter could be considered an anti-vascular effect. More recently, 
we have found that this novel treatment approach may also address 
another cancer hallmark, evasion of immune surveillance. The 
strategy, discussed below, uses pulsed power technology that delivers 
nanosecond pulsed electric fields (nsPEFs) directly to tumors.
During developmental and homeostatic cell death, apoptosis is 
anti-inflammatory and immunologically silent or tolerogenic [13]. 
Although some studies show that necrotic cells can provoke an 
immune response [14-17], a number of recent studies indicate that 
caspase-dependent processes are important for immunogenicity [18]. 
In chemotherapy-induced cell death, some (anthracyclins), but not 
all (mitomycin C) caspase-inducing chemotherapeutic agents initiate 
immunogenic cell death [19]; thus, not all caspase-mediated apoptosis 
programs have the same impact on immune mechanisms. Apoptosis 
has been shown to induce maturation of dendritic cells leading to 
T-cell activation and immunity [20] and that apoptotic cells not only 
undergo degradation, but also deliver processed antigen to dendritic 
cells for cross-presentation [21]. Immunogenic cell death has obvious 
advantages for cancer treatment. In the last several years, it has been 
realized that there is a relatively specific set of cell death mechanisms 
that plays roles in immunogenic cell death. These include changes in 
cell surface membranes (externalized calreticulin binds to CD91 on 
dendritic cells enhancing engulfment), release of soluble factors that 
interact with a series of dendritic cell receptors to enhance antigen 
presentation to T-cells (HMGB1 binding toll-like receptors and ATP 
binding to purinergic P2RX7 stimulating IL-1β) and activation of the 
immune system against cancer [18]. Thus, there is increasing evidence 
that it is important to understand mechanisms of tumor cell death 
because they can provide a means to enhance immune responses and 
prevent recurrences through immunogenic cell death, whether by 
apoptosis and/or necrosis.
The approach for in vivo cancer treatment in my laboratory and 
others using nsPEFs [22-25] departs from targeting specific cancer 
“drivers” with mutation-specific targeted drugs, although treatment 
with nsPEFs should render most “drivers” inoperable. In evaluating 
effects of nsPEFs, they do affect several cancer hallmarks as indicated 
above. However, nsPEFs target the whole tumor as an organ at the 
primary site.
At the first international Evolution and Cancer Conference in 
June of 2011, Steven Neuberg, a social psychologist from Arizona 
State University in Tempe pointed out that a more apt metaphor for 
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cancer than “foreign invaders” is cancer as “criminal gangs” who as 
local residence have gone bad, slowly exploit the environment around 
them for their own gain. “Cancers are not outside the body, they come 
from within us”, he said [26]. In this concept, the criminal gang (the 
cancer) within the local community (cancer microenvironment) 
coerces the local population (“educating” supporting host cells) to 
use their resources (growth factors, signaling molecules) to thwart 
the authorities (evading immune surveillance) and support the gang’s 
criminal activity (the tumor behaving as an organ). Thus, the presence 
of cancer supplies a new, demanding organ, more aggressive than 
other organs in your body. Studies in my laboratory are investigating 
possibilities that nsPEF ablation goes beyond eliminating tumors at the 
primary site by alerting the immune system to the “criminal gang’s” 
cancer activities, thereby providing a protective, vaccine-like effect and 
preventing recurrences [27]. 
Pulsed power technology with nsPEFs ablates cancer by a non-
thermal, non-drug procedure. Using pulsed power, which has been 
used for decades in weaponry and high power physics, provides an 
innovative progression of pulsed power to application in basic science 
and cancer treatment, among other utilizations [28]. An example of 
pulsed power principles inherent in nsPEFs is to compare storage of one 
joule of energy released in one second (1 watt) versus released in one 
microsecond (1 megawatt) or one nanosecond (1 gigawatt). The latter is 
enough power to light an intermediate-sized city for that nanosecond. 
The high power eliminates cells by programmed cell death. It does not 
immediately “blow cells away”; cell death is delayed and mechanisms 
are definable and quantifiable in vitro [29-35] and in vivo [12,27,36,37]. 
Cells ultimately die by programmed cell death mechanisms that include 
both caspase-dependent (or -associated) and caspase-independent cell 
death, which requires further characterization.
We continue to develop a local treatment modality with nsPEFs 
using an orthotopic rat N1-S1 hepatocellular carcinoma (HCC) 
model with the likelihood to enhance immune function [27,37]. 
In the world population, incidence and mortality rates of HCC are 
nearly equal, symptoms and diagnoses generally occur at advanced 
stages and prognoses are usually poor. Diagnoses of younger people 
have increased in the US mostly due to increases in hepatitis C and B 
infections. However, early diagnoses are more common due to greater 
awareness, new screening approaches and high-resolution imaging 
of the liver, providing more definitive diagnoses [38]. Presentation 
and treatment considerations of HCC are unique compared to other 
cancers because the prognosis not only depends on tumor size, but also 
on underlying diseases such as cirrhosis or other hepatic functional 
maladies [39]. Major problems for HCC treatment include less than 
20% patient eligibility for resection because of underlying liver disease 
and/or tumor position near vital structures. Furthermore, there are 
no management strategies that avoid multiple treatments and prevent 
recurrences. These problems are resolvable because nsPEF treatment 
has sharply defined treatment zones determined by the electrode design, 
which only affects tissues within electrodes surrounding the tumor. 
This requires a single treatment and after ablation offers a protection 
or resistance to further tumor growth [27]. It therefore appears to 
vaccinate against the same cancer, thereby preventing recurrences. 
There are a number of alternative treatments to surgery and 
drugs with several relatively new technologies for treating HCC using 
thermal approaches (radiofrequencies, microwaves, cryoablation), 
chemical techniques (percutaneous ethanol / acetic acid), radiological 
methods (ionizing radiation, transarterial chemoembolization and 
radioembolization), high frequency ultrasound (HIFU) treatment 
and irreversible electroporation [40-45]. However, while some of 
these methods have had some success, all of these most often require 
multiple treatments and recurrences are common. Thermal and 
chemical methods of ablation are taken from 16th century medicine 
when Ambroise Pare, a self-taught “surgeon”, described charring 
tumors with a coal-heated soldering iron or scorching them with 
a paste of sulfuric acid [46]. Patients with HCC are generally spared 
chemotherapeutic drug treatment, because HCCs are notoriously 
resistant to chemotherapeutic agents and radiation. Even the new oral 
multi-kinase inhibitor sorafenib for advanced HCC has only rather 
modest clinical efficacy extending survival by only 7-10 months [47,48].
There are numerous advantages for using nsPEF ablation as a means 
for cancer therapy as opposed to other physical and chemical methods, 
radiofrequency ablation (RFA), radiation or chemotherapeutic agents. 
(However, nsPEFs have been shown in combination with gemcitabine 
to provide synergistic cytotoxic responses [49]). NsPEF ablation 
(1) targets multiple programmed cell death mechanisms that evade 
apoptosis induction and promote angiogenesis [12,36], two well-known 
cancer hallmarks; (2) can induce cell death in the absence of FADD, 
caspase-8 and APAF-1, which bypasses cancer-causing mutations that 
block death receptor pathways and caspase activation [32]; (3) targets 
mitochondria-mediated programmed cell death [30,32,50,51] even in 
the presence of Bcl-xl overexpression, which protects mitochondria 
[Beebe et al., unpublished]; (4) provides well-defined treatment zones 
that focus treatments to the tumor and marginal tissue surrounded by 
electrodes, which minimizes damage to healthy surrounding tissue 
[52]; (5) exhibits broad specificity for cell death induction in tumor 
masses and the microenvironment, which includes rapidly growing 
tumor cells, slower growing host cells that collaborate with tumor cells 
and cancer stem cells; (6) requires a single treatment lasting about 
17 minutes with rapid tumor disappearance [27], which avoids long 
treatment times that allow chances for resistance-causing mutations 
that lead to recurrences; (7) exhibits minimal local and systemic 
side effects; (8) induces local infarction of small vessels [12,36] and 
transiently reduces blood flow to tumors, yet recovers to allow inflow 
of immune cells [27]; and (9) provides a protective, vaccine-like effect 
in ectopic mouse and orthotropic rat models for HCC [27]; this shows 
that this protective effect is independent of species or tumor location. 
We hypothesize that this is likely due to enhanced immune surveillance 
from cells undergoing nsPEF-induced cell death, thus addressing 
another cancer hallmark [27].
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